Mescaline Facts
Psychedelic;
Description
Mescaline is a naturally-occurring psychedelic of the phenethylamine class. It activates serotonin receptors in the brain, disrupting the normal filtering of sensory input and producing the visual and emotional shifts characteristic of classical psychedelics.[1]
Subjective effects include geometric visual patterns, color enhancement, time alteration, thought acceleration, and a warmth and openness toward others. The experience unfolds slowly over the better part of a day — broader and warmer in feel than LSD, with an interpersonal openness attributed in part to mescaline's unique elevation of oxytocin.[2]
Mescaline produces no physical dependence and no lethal dose has been established in humans — rapid tolerance after a single use makes compulsive redosing self-limiting.[3][4] The primary risks are psychological — acute anxiety, panic, and potential triggering of psychotic episodes in predisposed individuals — and blood pressure rises consistently, which matters for anyone with cardiovascular conditions.[5]
Dose and durationby route · individual sensitivity varies
Starts in 20 – 45 minLasts 6 – 14 hoursAfter-effects 6 – 36 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- LSD;
psilocybin; DMT; 2C-B
Effectslikely at a common dose
- Perception
- Color enhancement;
Visual drifting; Color alteration; Music enhancement; Geometry; Visual breathing; +29 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise - Body
- Stimulation;
Pupil dilation; Nausea; Wakefulness; Body scan awareness; +37 possible, including Insomnia, Vomiting, Muscle tension - Thinking
- Pattern recognition enhancement;
Novelty enhancement; Aesthetic enhancement; Introspection enhancement; +33 possible, including Suggestibility enhancement, Cognitive impairment, Decision impairment - Feeling
- Emotional enhancement;
+8 possible, including Anxiety, Emotional lability, Dysphoria - Self
- none likely · 9 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- Personal insight;
+3 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]
- [2]^Ley L, Holze F, Arikci D, Becker AM, Straumann I, Klaiber A, Coviello F, Dierbach S, Thomann J, Duthaler U, Luethi D, Varghese N, Eckert A, Liechti ME (2023) Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants — Neuropsychopharmacology doi:10.1038/s41386-023-01607-2
- [3]
- [4]^Krebs TS, Johansen PO (2013) Psychedelics and mental health: a population study — PLoS ONE doi:10.1371/journal.pone.0063972
- [5]^Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F (2017) The 'Endless Trip' among NPS Users: Psychopathology and Psychopharmacology in HPPD. A Systematic Review — Frontiers in Psychiatry doi:10.3389/fpsyt.2017.00240